In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% rate of ...
The blockbuster diabetes and weight loss drug semaglutide (Wegovy, Ozempic, Rybelsus) reduced the relative risk of heart attack, stroke, or cardiovascular deaths by 20 percent in high-risk patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results